AtriCure, Inc. (ATRC): Results of Operations and Financial Condition
AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-7232026.htm EX-99.1 Document Exhibit 99.1 For immediate release July 23, 2026 AtriCure Reports Second Quarter 2026 Financial Results • Second Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year • Second Quarter 2026 profitabi
How this was made
The 30-second read
Why it matters
The combination of Q2 beat on profitability (net income and higher adjusted EBITDA) and explicit FY2026 guidance creates a clear repricing opportunity for ATRC’s growth and margin trajectory.
Market read
Traders can update models immediately using the disclosed Q2 datapoints and FY2026 guidance ranges.
What to watch
The release emphasizes non-GAAP metrics (adjusted EBITDA/EPS) and mix/manufacturing efficiencies; traders may discount sustainability if gross margin tailwinds reverse.
Background
This SEC 8-K reports AtriCure’s Q2 2026 results and provides full-year 2026 guidance, including revenue, adjusted EBITDA, and EPS ranges.
Ticker impact
AtriCure reported Q2 2026 revenue of $153.6M (+12.8% YoY), net income of $9.0M, and guided FY2026 revenue to $602M-$610M.
Likely positive near-term bias as traders reprice FY2026 growth and margin expectations; magnitude depends on how the market compares guidance to consensus.
The filing includes fresh, primary financial results and forward guidance ranges (revenue, adjusted EBITDA, EPS) rather than a recap of previously known numbers.
Market effects
Supports sentiment for cardiac surgery and Afib device peers by signaling demand strength in pain management and appendage management franchises.
U.S. revenue growth (up 13.6% YoY) suggests domestic procedure volumes and reimbursement conditions are contributing.
International revenue grew 9.6% (7.1% constant currency), indicating some resilience outside the U.S.
Counterpoint
Guidance includes a wide revenue range and EPS range; if investors expected a tighter beat, the stock reaction could be muted despite Q2 strength.
Key entities
- companyAtriCure, Inc.
Subject of the 8-K, reporting Q2 2026 financial results and FY2026 guidance.
- clinical_trialsBoxX-NoAF and LeAAPS
Clinical trials referenced as progressing toward data readouts that could influence future growth expectations.
